# A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Study · id `cardio:ct-nct01475825` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01475825](<https://clinicaltrials.gov/study/NCT01475825>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01475825

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 309 participants.

## Technical summary

Registry record NCT01475825. Randomized; quadruple masking; primary purpose treatment. Start 2011-12 (actual); primary completion 2015-12-29 (actual). Results posted on 2019-03-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 309 participants (enrolled count; ClinicalTrials.gov record NCT01475825, source copy `cardio:ctgov-nct01475825-2019-03-26`, retrieved 2026-10-31)
- Started: 2011-12 (actual) (ClinicalTrials.gov record NCT01475825, source copy `cardio:ctgov-nct01475825-2019-03-26`, retrieved 2026-10-31)
- Primary completion: 2015-12-29 (actual) (ClinicalTrials.gov record NCT01475825, source copy `cardio:ctgov-nct01475825-2019-03-26`, retrieved 2026-10-31)
- Completion: 2015-12-29 (actual) (ClinicalTrials.gov record NCT01475825, source copy `cardio:ctgov-nct01475825-2019-03-26`, retrieved 2026-10-31)
- Results first posted: 2019-03-14 (ClinicalTrials.gov record NCT01475825, source copy `cardio:ctgov-nct01475825-2019-03-26`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Croatia; Czechia; Denmark; Germany; Greece; Hong Kong SAR China; Hungary; India; Israel; Italy; Malaysia; Netherlands; New Zealand; Norway; Poland; Russia; South Africa; South Korea; Spain; Sweden; Taiwan; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01475825, source copy `cardio:ctgov-nct01475825-2019-03-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01475825-2019-03-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
- Acronym: FOCUS FH
- Condition: Hypercholesterolemia
- Condition: Heterozygous Familial
- Intervention (Drug): mipomersen sodium 200 mg
- Intervention (Drug): Placebo
- Intervention (Drug): mipomersen sodium 70 mg
- Lead sponsor: Kastle Therapeutics, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

## Provenance

Content hash: 121076dead6cbc7835b8c9ee4581246d14dbf8bd7a13c36baaa611f5303c5c1f
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
